{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:31:50Z","timestamp":1793277110690,"version":"4.5.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fitness tracking, facilitated by wearable devices, has emerged as a\u00a0popular method for monitoring physical activity levels in the general population; however, its usage, acceptance and utility in patients with multiple sclerosis (pwMS) remain understudied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the prevalence of fitness tracking device usage in pwMS and to explore acceptance and willingness to share data for use in healthcare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We surveyed a\u00a0cohort of consecutively and prospectively included pwMS diagnosed according to revised McDonald criteria 2017 in MS outpatient departments from two centers in Bern, Switzerland and Vienna, Austria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of a total of 200 pwMS (70% female) with a mean age of 43.1\u00a0years (SD 12.3\u00a0years), 161\/200 (80.5%) had relapsing MS. Overall, 34.0% pwMS reported wearing a\u00a0fitness tracker and when asked how often they actually wear their fitness tracker, 54.4% reported wearing it always and 27.9% reported wearing it often, whereas only 16.2% reported infrequent use. Asked whether they would share the data gathered by their respective fitness tracker, 93.9% reported a\u00a0willingness to share their health data for both clinical routine care and research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a\u00a0representative cohort of pwMS in Central Europe, about one third are already actively and frequently tracking their physical activities with a\u00a0strong dedication to utilizing their tracking data within healthcare settings including research. This underscores the feasibility and significant potential utility of monitoring physical activity by fitness tracking in the realm of MS care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00508-026-02774-0","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:15:25Z","timestamp":1781543725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Monitoring physical activity by fitness tracking devices"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3486-3448","authenticated-orcid":false,"given":"Helly","family":"Hammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hoepner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Louise","family":"Aicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Habernig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Leutmezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Rommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Nef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"17 Suppl","key":"2774_CR1","first-page":"s321","volume":"19","author":"K Noyes","year":"2013","unstructured":"Noyes\u00a0K, Weinstock-Guttman\u00a0B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care. 2013;19(17 Suppl):s321\u2013s31.","journal-title":"Am J Manag Care"},{"issue":"4","key":"2774_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.7224\/1537-2073.2018-087","volume":"22","author":"AD Bass","year":"2020","unstructured":"Bass\u00a0AD, Van Wijmeersch\u00a0B, Mayer\u00a0L, M\u00e4urer\u00a0M, Boster\u00a0A, Mandel\u00a0M, et\u00a0al. Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey. Int J MS Care. 2020;22(4):158\u201364.","journal-title":"Int J MS Care"},{"issue":"10","key":"2774_CR3","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1080\/09638288.2022.2069295","volume":"45","author":"L Andreu-Caravaca","year":"2023","unstructured":"Andreu-Caravaca\u00a0L, Ramos-Campo\u00a0DJ, Chung\u00a0LH, Mart\u00ednez-Rodr\u00edguez\u00a0A, Rubio-Arias\u00a0J. Effects and optimal dosage of resistance training on strength, functional capacity, balance, general health perception, and fatigue in people with multiple sclerosis: a systematic review and meta-analysis. Disabil Rehabil. 2023;45(10):1595\u2013607.","journal-title":"Disabil Rehabil"},{"key":"2774_CR4","doi-asserted-by":"crossref","unstructured":"Hao Z, Zhang X, Chen P. Effects of Different Exercise Therapies on Balance Function and Functional Walking Ability in Multiple Sclerosis Disease Patients\u2011A Network Meta-Analysis of Randomized Controlled Trials. Int J Environ Res Public Health. 2022;19(12).","DOI":"10.3390\/ijerph19127175"},{"issue":"10","key":"2774_CR5","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1177\/1352458519857075","volume":"25","author":"G Brichetto","year":"2019","unstructured":"Brichetto\u00a0G, Pedull\u00e0\u00a0L, Podda\u00a0J, Tacchino\u00a0A. Beyond center-based testing: Understanding and improving functioning with wearable technology in MS. Mult Scler. 2019;25(10):1402\u201311.","journal-title":"Mult Scler"},{"issue":"3","key":"2774_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00421777","volume":"37","author":"WH Saris","year":"1977","unstructured":"Saris\u00a0WH, Binkhorst\u00a0RA. The use of pedometer and actometer in studying daily physical activity in man. Part\u00a0I:\u00a0reliability of pedometer and actometer. Eur J Appl Physiol Occup Physiol. 1977;37(3):219\u201328.","journal-title":"Eur J Appl Physiol Occup Physiol"},{"issue":"2","key":"2774_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich\u00a0DS, Lucchinetti\u00a0CF, Calabresi\u00a0PA. Multiple Sclerosis. N Engl J Med. 2018;378(2):169\u201380.","journal-title":"N Engl J Med"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02774-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-026-02774-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02774-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:37:55Z","timestamp":1793273875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-026-02774-0"}},"subtitle":["Usage, acceptance and willingness to share data in patients with multiple sclerosis"],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":7,"alternative-id":["2774"],"URL":"https:\/\/doi.org\/10.1007\/s00508-026-02774-0","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.\u00a0Hammer has received speaker\/advisor remuneration from Biogen, Janssen, Novartis, Merck, Roche, Teva. She received research support within the last 5\u00a0years from Biogen. She received travel grants from Biogen, Roche, Janssen, Merck. R.\u00a0Hoepner has received speaker\/advisor remuneration from Merck, Novartis, Roche, Biogen, Alexion, Sanofi, Janssen, Bristol-Myers Squibb, Teva\/Mepha and Almirall. He received research support within the last 5\u00a0years from Roche, Merck, Sanofi, Biogen, Chiesi, and Bristol-Myers Squibb. He also received research grants from the Swiss MS Society, the SITEM Insel Support Fund and is a\u00a0member of the Advisory Board of the Swiss and International MS Society. He also serves as deputy editor in chief for the\n                      Journal of Central Nervous System Disease\n                      . All conflicts are not related to this work. F.\u00a0Leutmezer has participated in meetings sponsored by, received speaker honoraria or travel funding from Actelion, Almirall, Biogen, Celgene, Johnson&Johnson, MedDay, Merck, Novartis, Roche, Sanofi and Teva, and received honoraria for consulting Biogen, Celgene, Merck, Novartis, Roche, Sanofi and Teva.. P.\u00a0Rommer has received remuneration for consultancy\/speaking from Alexion\/Astra Zenace, Allmiral, Biogen, Horizion\/Amgen, Merck, Novartis, Roche, Sandoz, Sanofi, has received research grants from Amicus, Biogen, Merck, Roche. A.\u00a0Chan has received speakers\u2019\/board remuneration from Actelion (Janssen\/J&J), Alexion, Almirall, Bayer, Biogen, Celgene (BMS), Genzyme, Merck KGaA (Darmstadt, Germany), Novartis, Roche, and Teva, all for hospital research funds. He received research support from Biogen, CSL Behring, Genzyme, and UCB, the European Union, and the Swiss National Foundation. T.\u00a0Berger has participated in meetings sponsored by and received remuneration (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Bayer, Biogen, Bionorica, BMS\/Celgene, Genesis, GSK, GW\/Jazz Pharma, Horizon, Janssen-Cilag, MedDay, Merck, Novartis, Octapharma, Roche, Sandoz, Sanofi-Genzyme, Teva and UCB. His institution has received financial support in the past 12\u00a0months by unrestricted research grants (Biogen, Bayer, BMS\/Celgene, Merck, Novartis, Roche, Sanofi-Genzyme, Teva and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, Teva). G.\u00a0Bsteh has participated in meetings sponsored by, received speaker remuneration or travel funding from Biogen, BMS, Janssen, Lilly, Medwhizz, Merck, Neuraxpharm, Novartis, Roche, Sanofi and Teva, and received remuneration for consulting from Adivo Associates, Biogen, BMS, Janssen, Merck, Novartis, Roche, Sanofi and Teva. He has received unrestricted research grants from BMS and Novartis. He serves on the Executive Committee of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Board of Directors of the International Multiple Sclerosis Visual System Consortium (IMSVISUAL). M.L. Aicher, S. Habernig and T.\u00a0Nef, declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}